Answers are grounded in this paper and cite their sources.
This analysis develops a race-aware model using DNA methylation data to classify prostate cancer stages, highlighting limitations in minority populations.
BACKGROUND Prostate cancer progression exhibits significant variability influenced by biological and racial factors. DNA methylation profiling has shown potential in early cancer detection, but its integration with machine learning across racially diverse populations remains limited. OBJECTIVE This study aims to develop a race-aware framework using DNA methylation data and a Multi-Layer Perceptron (MLP) model to classify prostate cancer stages into early (I–II) and late (III–IV) stages. METHODS Methylation and phenotype data from the TCGA-PRAD dataset were processed using Differentially Methylated Positions (DMP) analysis to identify CpG sites correlated with cancer stages. These features were further refined through Recursive Feature Elimination (RFE) and used to train MLP models. SHapley Additive exPlanations (SHAP) and Local Interpretable Model-Agnostic Explanations (LIME) were used to interpret the model and identify key DNA methylation features contributing to model predictions. RESULTS The best-performing model achieved ~95% accuracy and up to 99% AUC on the majority race (White) training data using 70 selected features. However, performance declined sharply on minority race groups, revealing the effects of sample imbalance and race-specific methylation patterns. Feature importance examination indicates strong patterns within certain CpG sites driving the models predictions. CONCLUSIONS We propose a race-aware MLP model for prostate cancer stage classification using DNA methylation data, optimized through DMP and RFE-based feature selection. SHAP and LIME confirmed the predictive relevance of selected CpG sites, supporting model transparency. Results highlight high performance within the White cohort but reveal poor generalization to minority groups, emphasizing the importance of race-specific modeling strategies.
No takes yet. Share an insight, caveat, or question.
Mulia et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: